Temperature-Stable Vaccine Formulations with Sugar Stabilizers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines containing aluminum adjuvants require a cold chain for storage and distribution, which is expensive and prone to failures, leading to potential potency loss and aggregation of aluminum particles upon freezing, limiting their use in resource-constrained settings and emergency situations.
Innovation Solution
Development of temperature-stable vaccine formulations with at least 20% sugar as a stabilizer, combined with amino acids and surfactants, which prevent alum gel collapse and maintain potency even after freezing and thawing, allowing for lyophilization and storage without the need for a cold chain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines containing aluminum adjuvants are stored and distributed using cold chain (2-8°C), then vaccine potency is maintained, but storage and distribution costs increase and reliability decreases due to equipment failure and resource constraints
Solution Approach 1:
The invention changes the temperature parameter range for vaccine storage by formulating vaccines with stabilizers (sugars, amino acids, surfactants) that enable stability across a broader temperature range (-20°C to 50°C), eliminating dependence on the narrow 2-8°C cold chain window
Solution Approach 2:
The invention extracts and addresses the root cause of cold chain dependence by removing the vulnerability to temperature fluctuations through formulation modifications, specifically adding stabilizers that protect against freezing and heat-induced degradation
2Reliability
If vaccines containing aluminum adjuvants are frozen, then cold chain equipment failures are masked, but alum gel collapse and aggregation occur leading to potency loss
Solution Approach 1:
The invention applies beforehand cushioning by incorporating stabilizers (sugars, amino acids, surfactants) into the vaccine formulation that preemptively protect the alum gel structure from damage during freezing and thawing cycles, preventing aggregation and maintaining potency
Solution Approach 2:
The invention creates a composite vaccine formulation combining aluminum adjuvant with stabilizing agents (sugars, amino acids, surfactants) that work synergistically to maintain structural integrity across temperature extremes
3Reliability
If vaccines require cold chain storage, then potency is maintained, but distribution speed and accessibility decrease in resource-constrained settings
Solution Approach 1:
The invention expands the acceptable temperature parameter range for vaccine storage from the narrow 2-8°C window to a broad range (-20°C to 50°C), enabling rapid distribution without refrigeration infrastructure and improving accessibility in remote areas
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations exhibit little to no reduction in potency and alum gel collapse, ensuring stability and immunogenicity after freeze/thaw cycles, enabling broader distribution and storage without the need for refrigeration, including at elevated temperatures.
Implementation Method 1
Development of temperature-stable vaccine formulations with at least 20% sugar as a stabilizer, combined with amino acids and surfactants, which prevent alum gel collapse and maintain potency even after freezing and thawing
Implementation Method 2
allowing for lyophilization and storage without the need for a cold chain
Data Source
AI summary
Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.